pharmaphorum3d
FDA rejection of Spero's tebipenem 'raises resistance threat'
The FDA's decision not to approve Spero Therapeutics' oral antibiotic tebipenem Hbr for adults with complicated urinary tract infections (cUTI) further increases the threat of antibiotic ...
pharmaphorum6d
Undeterred by FDA setback, GSK snaps up Spero antibiotic
GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults with ...
yr.no2d
Spero Lake
It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...